Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junye Wang

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Nature Communications|September 26, 2022
USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancerDongni Shi, Xianqiu Wu, Yunting Jian, et al.
JAMA|February 24, 2025
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical TrialXiaotian Zhang, Jufeng Wang, Gang Wang, et al.
Current Oncology (Toronto, Ont.)|April 30, 2021
Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung AdenocarcinomaQiwen Li, Li Ma, Bo Qiu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 28, 2014
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)Xingsheng Hu, Baohui Han, Aiqin Gu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)NaiBin Chen, QiWen Li, SiYu Wang, et al.
Signal Transduction and Targeted Therapy|May 6, 2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Yi Ba, Junye Wang, et al.
Signal Transduction and Targeted Therapy|August 20, 2025
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 studyGuoming Shi, Xiaoyong Huang, Liang Ma, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 11, 2025
Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III studyYaxin Liu, Ruyan Zhang, Xiaojia Wang, et al.
Technology in Cancer Research & Treatment|February 2, 2023
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial ProtocolJinjie He, Yue Liu, Chengcheng Liu, et al.
Nature Communications|September 15, 2021
Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancerHuaqiang Zhou, Yi Hu, Rongzhen Luo, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Nature Communications|September 26, 2022
USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancerDongni Shi, Xianqiu Wu, Yunting Jian, et al.
JAMA|February 24, 2025
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical TrialXiaotian Zhang, Jufeng Wang, Gang Wang, et al.
Current Oncology (Toronto, Ont.)|April 30, 2021
Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung AdenocarcinomaQiwen Li, Li Ma, Bo Qiu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 28, 2014
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)Xingsheng Hu, Baohui Han, Aiqin Gu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)NaiBin Chen, QiWen Li, SiYu Wang, et al.
Signal Transduction and Targeted Therapy|May 6, 2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Yi Ba, Junye Wang, et al.
Signal Transduction and Targeted Therapy|August 20, 2025
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 studyGuoming Shi, Xiaoyong Huang, Liang Ma, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 11, 2025
Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III studyYaxin Liu, Ruyan Zhang, Xiaojia Wang, et al.
Technology in Cancer Research & Treatment|February 2, 2023
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial ProtocolJinjie He, Yue Liu, Chengcheng Liu, et al.
Nature Communications|September 15, 2021
Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancerHuaqiang Zhou, Yi Hu, Rongzhen Luo, et al.
Pageof 10